6th International C. difficile Symposium

12th to 14th September 2018 Bled, Slovenia

6th ICDS 2018 ABSTRACT BOOK

On-line version of the Abstrakt book  is available here.

6th ICDS 2018 PROGRAMME

Wednesday, September 12th
SESSION I: 15:00-16:45 - MICROBE AND HOST
15:00-15:15Rupnik, M.OPENING
15:15-15:45INV1Britton, R.Clostridium difficile ADAPTATIONS TO THE DIET: IMPLICATIONS FOR HUMAN DISEASE AND ANIMAL CARRIAGE
15:45-16:15INV2Vedantam, G.C. DIFFICILE COLONIZATION AND VIRULENCE: A COMPLEX INTERPLAY BETWEEN TOXIN AND NON-TOXIN FACTORS
16:15-16:45COFFEE BREAK
SESSION II: 16:45-18.15 - SHORT ORAL PRESENTATIONS I
16:45-17:00OP1Dorr, M.B.INSIGHTS FROM FIDAXOMICIN, BEZLOTOXUMAB AND SUROTOMYCIN CLINICAL TRIALS: LOOKING BEYOND THE PRIMARY ANALYSES
17:00-17:15OP2Kokai-Kun, J.F.SYn-004 (RIBAXAMASE) PREVENTED Clostridium difficile INFECTION IN PATIENTS BEING TREATED WITH BETA-LACTAM ANTIBIOTICS
17:15-17:30OP3Heidebrecht, H. J. TREATMENT AND PREVENTION OF Clostridium difficile INFECTION WITH FUNCTIONALIZED BOVINE ANTIBODY-ENRICHED WHEY IN A HAMSTER PRIMARY INFECTION MODEL
17:30-17:45OP4Mitra, S.COMPARATIVE METAGENOMICS OF GUT MICROBIOME: RIDINILAZOLE IS ASSOCIATED WITH PRESERVATION OF MICROBIOME COMPARED WITH FIDAXOMICIN DURING TREATMENT OF Clostridium difficile INFECTION.
17:45-18:00OP5Dupuy, B. ROLE OF DEOXYCHOLATE IN INDUCTION OF Clostridium difficile BIOFILM FORMATION
18:00-18:15OP6Shaw, P.M.GENOME WIDE ANALYSIS REVEALS HOST GENETIC VARIANTS THAT ASSOCIATE WITH REDUCTION IN Clostridium difficile INFECTION RECURRENCE IN PATIENTS TREATED WITH BEZLOTOXUMAB
19:30WELCOME RECEPTION (Hotel Rikli Balance)
Thursday, September 13th
PRO CON DEBATE: 8:30-10:00 - FMT or ANTIBIOTIC MANAGEMENT
8.30-8.55INV3Johnson, S.FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR C. difficile INFECTION: JUST SAY NO
8:55-9:20INV4Cammarota, G. FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR C. difficile INFECTION: JUST SAY YES
9:20-10:00DISCUSSION
10:00-10:30COFFEE BREAK
SESSION III: 10:30-12:00 - SHORT ORAL PRESENTATIONS II
10:30-10:45OP7Vendrik, K.Clostridioides difficile PCR RIBOTYPE 023 PRESENTS AS SEVERE DISEASE WITH A COMMUNITY ONSET
10:45-11:00OP8Magnusson, C.INCREASED MORTALITY IN A Clostridium difficile OUTBREAK DUE TO PCR RIBOTYPE 046
11:00-11:15OP9Golding, G.R.MOLECULAR CHARACTERIZATION OF HEALTHCARE-ASSOCIATED Clostridium difficile INFECTIONS 2007-2016, CANADA
11:15-11:30OP10Stone, N.E.ANALYSIS OF TOXIGENIC Clostridium difficile IN CANINES SUGGESTS THAT MICROBIAL MEMBERS OF THE CANINE GUT MAY PROVIDE RESISTANCE TO DISEASE
11:30-11:45OP11Oliveira, P.H.EPIGENOMIC LANDSCAPE OF THE HUMAN PATHOGEN Clostridium difficile
11:45-12:00OP12Whittle, M.IDENTIFICATION OF THE Clostridioides difficile BACTERIOPHAGE RECEPTOR
12:00-13:00LUNCH (Hotel Rikli Balance)
13:00-14:00POSTER SESSION + networking
PRO CON DEBATE: 14:00-15:30 - DIAGNOSTICS - PRO PCR, CON PCR
14:00-14:25INV5Fang, F.NUCLEIC ACID AMPLIFICATION TESTING IS THE BEST APPROACH TO DIAGNOSE Clostridium difficile INFECTIONS
14:25-14:50INV6Wilcox, M.USE OF NUCLEIC ACID AMPLIFICATION TESTS (NAATs) ALONE IS NOT SUITABLE FOR THE DIAGNOSIS OF Clostridium difficile INFCTION
14:50-15:30DISCUSSION
15:30-16:00COFFEE BREAK
SESSION IV: 16:00-17:00 - EMERGING TECHNOLOGIES
16:00-16:30INV7Sorg, J.CRISPR-CAS9 GENOME EDITING IN C. difficile
16:30-17:00INV8Janoir, C.IN VIVO VISUALIZATION OF Clostridium difficile AND BIOFILMS
17:00POSTER SESSION + NETWORKING + BEER TASTING
Friday, September 14th
SESSION V: 8:30-10:00 - PATHOGENESIS - MICROBE
8:30-9:00INV9Fortier, L.C.C. difficile PHAGES
9:00-9:30INV10Salgado, P.C. difficile SPORULATION: ENGULFMENT MACHINERIES AND MECHANISMS
9:30-10:00INV11Tamayo, R.PHASE VARIATION IN Clostridium difficile : MECHANISMS AND PHENOTYPIC OUTCOMES
10:00-10:30COFFEE BREAK
SESSION VI: 10:30-12:00 - SHORT ORAL PRESENTATIONS III
10:30-10:45OP13Maikova, A.THE CRISPR-CAS SYSTEM OF HUMAN PATHOGEN Clostridium difficile : FUNCTION AND REGULATION
10:45-11:00OP14Sekulovic, O.GENOME-WIDE PROFILING OF CONSERVATIVE SITE-SPECIFIC RECOMBINATION IN Clostridium difficile
11:00-11:15OP15Cuenot, E.ROLE OF THE S/T KINASE PrkC IN THE PHYSIOLOGIE OF C. difficile
11:15-11:30OP16Coullon, H.MURAMIC-δ-LACTAMS ARE INVOLVED IN C. difficile SPORULATION, GERMINATION AND VIRULENCE
11:30-11:45OP17McBride, S.M.REGULATION OF TOXIN PRODUCTION AND SPORULATION IN Clostridium difficile BY THE MULTIFUNCTIONAL PROTEIN, RstA
11:45-12:00OP18Soutourina, O.REGULATORY RNAS IN Clostridium difficile : DISCOVERY OF NEW TYPE I TOXIN-ANTITOXIN SYSTEMS ASSOCIATED WITH CRISPR ARRAYS
12:00-13:00LUNCH (Hotel Rikli Balance)
13:00-14:00POSTER SESSION + networking
SESSION VII 14:00-15:30 - CONTROL AND PREVENTION
14:00-14:30INV12Donskey, C.INFECTION CONTROL OF Clostridium difficile
14:30-15:00INV13Crobach, M.ASYMPTOMATIC COLONISATION WITH Clostridium difficile
15:00-15:30INV14Davies, K.THE FACTORS AFFECTING REPORTED CDI RATES
15:30-16:00COFFEE BREAK
SESSION VIII: 16:00-17:30 - COMPARATIVE GENOMICS
16.00-16.30INV15Knight, D.ONE HEALTH: THE OPTIMAL PARADIGM FOR STUDYING EVOLUTION AND TRANSMISSION IN C. difficile
16:30-17:00INV16Eyre, D.C. difficile TRANSMISSION IN THE HOSPITAL AND THE DIVERSE RESERVOIRS
17:00-17:30INV17Smits, W.K.DECRYPTING PLASMIDS: STABLE METRONIDAZOLE RESISTANCE IN Clostridium difficile CORRELATES WITH A PLASMID
19.00CONGRESS DINNER (Grand Hotel Toplice)
Menu